Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

suvorexant

suvorexant
  • Restricted Miscellaneous Programs
  • Restricted Belsomra --> Restricted to the continuation of therapy.
  • Therapeutic Interchange
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Belsomra TABLET, ORAL 5 mg, 10 mg    
Belsomra TABLET, ORAL 15 mg, 20 mg    


Comments:

ORDER FORMULATION

THERAPEUTIC INTERCHANGE

NOTES

suvorexant (Belsomra)

  • 5 mg tablet oral
  • 10 mg tablet oral

zolpidem (Ambien)

  • 5 mg tablet oral
  • 5 mg tablet oral

Interchange orders for new starts to zolpidem. Belsomra is dispensed from pharmacy for patients continuing a home regimen

suvorexant (Belsomra)

  • 15 mg tablet oral
  • 20 mg tablet oral

zolpidem (Ambien)

  • 10 mg tablet oral
  • 10 mg tablet oral

Interchange orders for new starts to zolpidem (not to exceed 5 mg for females). Belsomra is dispensed from pharmacy for patients continuing a home regimen

For Belsomra 15 mg, dispense three 5 mg tabs

For Belsomra 20 mg, dispense two 10 mg tabs


Belsomra medication guide


Belsomra is classified as formulary status, restricted to patients continuing a home regimen in the hospital. Orders for new starts are interchanged to zolpidem. Belsomra is a controlled substance and is dispensed from pharmacy rather than using a patient's own supply of medication


Reviewed: 23 June 2015 (Belsomra)


Last updated: Apr. 13, 2023







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.